Literature DB >> 27900875

Unprecedented success of rituximab therapy for prednisolone- and immunosuppressant-resistant systemic sclerosis-associated interstitial lung disease.

S Ebata1, A Yoshizaki1, T Fukasawa1, K Nakamura1, T Yamashita1, S Miura1, R Saigusa1, Y Ichimura1, T Takahashi1, M Hirabayashi1, T Taniguchi1, K Akamata1, Y Asano1, S Sato1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27900875     DOI： 10.1080/03009742.2016.1231341

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN： 0300-9742            Impact factor:   3.641


× No keyword cloud information.
  2 in total

Review 1.  Is biological therapy in systemic sclerosis the answer?

Authors:  Durga Prasanna Misra; Sakir Ahmed; Vikas Agarwal
Journal:  Rheumatol Int       Date:  2020-01-20       Impact factor: 2.631

2.  Rituximab treatment in patients with systemic sclerosis and interstitial lung disease.

Authors:  Abdel Gaffar A Mohammed; Ammar Alshihre; Ibrahim Abdulrazag Al-Homood
Journal:  Ann Thorac Med       Date:  2017 Oct-Dec       Impact factor: 2.219
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.